{"url_path":"/sec/galt/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1133416/0001140361-26-021495-index.html","accession_number":"0001140361-26-021495","cik":"0001133416","ticker":"GALT","issuer_name":"GALECTIN THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1133416/0001140361-26-021495-index.html","primary_entity_key":"0001133416","primary_entity_name":"GALECTIN THERAPEUTICS INC"},"word_count":44,"has_tables":true,"body_markdown":"Item 5.\n\nOther Information\n\n \n\nNone.\n\n \n\nSecurities Trading Plans of Directors and Executive Officers\n\n \n\nOur three executive officers, as defined in Rule 16a-1(f), each adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408, during the fiscal quarter ended March 31, 2026."}